Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric MATCH: Erdafitinib in FGFR-Altered Tumors
NCT03210714Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of erdafitinib in solid tumor, non-Hodgkin lymphoma (NHL), histiocytic disorder, sponsored by National Cancer Institute. Started Jun 2018; status: active, not recruiting.
02
Drugs
erdafitinib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)histiocytic disorder
Beyond the preview
Go deeper on NCT03210714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03210714.